Discovering Novel Biomarkers of Parkinson Disease

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 1565

Special Issue Editors

Department of Neurology and Neurosciences, Clínica Universidad de Navarra, Pamplona, Madrid, Spain
Interests: neurodegeneration; movement disorders; iron metabolism; Parkinson´s disease; biomarkers; magnetic resonance imaging; positron emission imaging
Centre for Neuroinflammation and Neurodegeneration, Neurology Imaging Unit, Imperial College London, London, UK
Interests: neurodegeneration; movement disorders; Parkinson´s disease; biomarkers; magnetic resonance imaging; positron emission imaging; PET methodology; functional MRI

Special Issue Information

Dear Colleagues,

Parkinson´s disease (PD) is the second most common neurodegenerative disorder, with a globally estimated prevalence of more than 8.5 million individuals. Unfortunately, disability due to PD is increasing faster than any other neurological disorders. The clinical diagnosis of PD is difficult in the early stages of the disease, with high risk of misdiagnosis (about 35% of cases) associated with difficulties in predicting the disease progression. There is a strong need for biomarkers for the correct diagnosis and monitoring of PD.

In recent decades, there has been an increase in knowledge regarding the pathophysiological mechanism underlying PD due to the development of neuroimaging and bio-fluid biomarkers, as well as advancements in the omics fields (metabolomics, proteomics, genomics and transcriptomics). Furthermore, digital biometry techniques are helping in the diagnosis and the monitoring of treatment in PD. The identification of robust biomarkers would help in the optimization of new therapeutic strategies that will also help in the early diagnosis and monitoring of the disease.

This Special Issue aims to include research studies and reviews, including clinical and preclinical studies focused on novels biomarkers in PD. We also aim to include review studies and meta-analyses that investigate the diagnostic or prognostic value of the identified potential PD biomarkers. Methodological articles that present novel neuroimaging biomarkers and validation will be particularly considered.

Dr. Antonio Martin-Bastida
Dr. Nick P. Lao-Kaim
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • magnetic resonance imaging
  • molecular imaging
  • omics
  • bio-fluid biomarkers
  • cerebrospinal fluid
  • digital biometry
  • Parkinson’s disease

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 1330 KiB  
Article
Adipokines, Vitamin D, and Selected Inflammatory Biomarkers among Parkinson’s Disease Patients with and without Dyskinesia: A Preliminary Examination
by Jan Milanowski, Jarosław Nuszkiewicz, Beata Lisewska, Paweł Lisewski and Karolina Szewczyk-Golec
Metabolites 2024, 14(2), 106; https://doi.org/10.3390/metabo14020106 - 05 Feb 2024
Viewed by 1080
Abstract
Parkinson’s disease (PD), a widely recognized neurodegenerative disorder, is characterized by a spectrum of symptoms including motor fluctuations and dyskinesia. Neuroinflammation and dysregulation of adipokines are increasingly implicated in the progression of PD. This preliminary study investigated the levels of inflammatory biomarkers and [...] Read more.
Parkinson’s disease (PD), a widely recognized neurodegenerative disorder, is characterized by a spectrum of symptoms including motor fluctuations and dyskinesia. Neuroinflammation and dysregulation of adipokines are increasingly implicated in the progression of PD. This preliminary study investigated the levels of inflammatory biomarkers and adipokines, namely interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), C-reactive protein (CRP), visfatin, progranulin, and 25(OH)-vitamin D in 52 PD patients, divided equally between those with and without dyskinesia and 26 healthy controls. Significant differences in the levels of IL-6, TNF-α, visfatin, and progranulin were noted between the groups. Patients with dyskinesia exhibited notably higher IL-6 levels compared to controls, and TNF-α was significantly elevated in both PD patient groups relative to the control group. Additionally, visfatin levels were higher in PD patients without dyskinesia as opposed to those with dyskinesia, and progranulin levels were elevated in the non-dyskinetic PD group compared to controls. The findings highlight the potential role of the examined biomarkers in the pathophysiology of PD. Changes in levels of the tested inflammatory biomarkers and adipokines might be associated with Parkinson’s disease and its symptoms such as dyskinesia. Full article
(This article belongs to the Special Issue Discovering Novel Biomarkers of Parkinson Disease)
Show Figures

Graphical abstract

Back to TopTop